Document is current

Article History

Received: 14 January 2017

Accepted: 6 March 2017

First Online: 20 March 2017

Compliance with ethical standards

:

: Author A. Stathis declares that has no conflict of interest. Author D. Hess declares that is shareholder of Novartis. Author R. von Moos declares that is advisory board participant of Novartis and BMS. Author K. Homicsko declares that has no conflict of interest. Author G. Griguolo declares that has no conflict of interest. Author M. Joerger declares that has no conflict of interest. Author M. Mark declares that has no conflict of interest. Author C.J. Ackermann declares that has no conflict of interest. Author S. Allegrini declares that has no conflict of interest. Author C.V. Catapano declares that has no conflict of interest. Author A. Xyrafas declares that has no conflict of interest. Author M. Enoiu declares that has no conflict of interest. Author S. Berardi declares that has no conflict of interest. Author P. Gargiulo declares that has no conflict of interest. Author C. Sessa declares that has no conflict of interest.

: The trial was conducted as an investigator initiated trial within the Swiss Group for Clinical Cancer Research (SAKK). Novartis provided sonidegib free of charge and financial support. This study was also supported by the Swiss State Secretariat for Education, Research and Innovation (SERI).

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

: Informed consent was obtained from all individual participants included in the study.